The Amsterdam Investigator-initiated Absorb Strategy All-comers Trial report safety concerns identified in early results for the bioresorbable scaffold drug eluting stent. The scaffold group experienced significantly higher rates of device thrombosis than the stent group (3.5% vs 0.9%; p<0.001).
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
May 12, 2017
A short and readable commentary on monoclonal antibodies and dyslipidaemias, particularly on FOURIER, SPIRE and ODYSSEY trials
Tracking the Evolution of Non-Small-Cell Lung Cancer- a DNA test that is 90% sensitive to detect recurrence up to a year before CT
May 8, 2017
Researchers conducted a study, published in Nature, to investigate whether this genetic diversity could be tracked clinically.
December 3, 2016
In this manuscript, the authors offer a comprehensive and thorough review of the pathophysiology of aortic stenosis and relate this to the different potential medical treatment options to slow down the progression of the disease.